[Ip-health] USTR Nat. Trade Barriers Report on Thai compulsory licenses

[Miles Teg]

Why should developing countries reduce their legal flexibility to
determine royalty rates by such "self regulation"? Is it a realistic
that opposition to CLs in developing countries would reduce?

bmt

mko wrote:
> I agree that middle-income countries should explore higher royalty rates on
> generically-priced drugs sold under a CL.  Doing so wouldn't harm access
> much; indeed if the higher royalty reduced opposition from USTR & IFPMA,
> then access could be dramatically improved.  I've tried to model these CL
> royalties or patent buy-outs from the opportunity cost in R&D from the
> foregone revenues:
>
> http://papers.ssrn.com/sol3/papers.cfm?abstract_id=873402
>
> Kevin Outterson
> Boston University
>
>
> On 4/1/08 9:54 AM, "B.Baker@neu.edu" <B.Baker@neu.edu> wrote:
>
>
>> I think there are four interest facets of the U.S. statement in the Thai
>> NTB report (reprinted below).
>>
>